In stage 1 , we randomly allocated patients 1:1 with the Pocock and Simon algorithm to intravenous rituximab ( 375 mg/m ( 2 ) ) or fixed-dose subcutaneous rituximab ( 1400 mg ) , stratified by induction chemotherapy regimen ( cyclophosphamide , doxorubicin , vincristine , prednisone or cyclophosphamide , vincristine , prednisone ) , Follicular Lymphoma International Prognostic Index score , and region .